# A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients

> **NCT02614560** · PHASE1,PHASE2 · TERMINATED · sponsor: **Seagen Inc.** · enrollment: 14 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** vadastuximab talirine
- **DRUG:** vadastuximab talirine

## Key facts

- **NCT ID:** NCT02614560
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11
- **Primary completion:** 2017-02-10
- **Final completion:** 2017-09-14
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2019-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02614560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02614560, "A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02614560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*